Lv11
54 积分 2023-10-16 加入
High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression
34分钟前
已完结
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
46分钟前
已完结
Lung Cancer Subtype Diagnosis by Fusing Image-Genomics Data and Hybrid Deep Networks
1个月前
已完结
Activity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer
2个月前
已完结
Structure-Based Discovery of Active Pan-KRas Inhibitors Targeting G12D Mutants by Enhanced Sampling Simulations
2个月前
已完结
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
2个月前
已完结
GSTA1 Conferred Tolerance to Osimertinib and Provided Strategies to Overcome Drug-Tolerant Persister in EGFR-Mutant Lung Adenocarcinoma
2个月前
已完结
GSTO1 aggravates EGFR-TKIs resistance and tumor metastasis via deglutathionylation of NPM1 in lung adenocarcinoma
2个月前
已完结
Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposures
2个月前
已完结
KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas
4个月前
已完结
皖公网安备34019202002308
